Acrivon Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Acrivon Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Acrivon Therapeutics, Inc. Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results for ACR-2316 At the 38Th EORTC-NCI-AACR Symposium
The story matters when it changes Acrivon Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.What makes Acrivon Therapeutics, Inc. (ACRV) a new buy stock
Investors are testing whether Acrivon Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?
Investors are testing whether Acrivon Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest ACRV filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Acrivon Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →